vs
INTEGRA LIFESCIENCES HOLDINGS CORP（IART）与Oportun Financial Corp（OPRT）财务数据对比。点击上方公司名可切换其他公司
INTEGRA LIFESCIENCES HOLDINGS CORP的季度营收约是Oportun Financial Corp的1.8倍（$434.9M vs $247.7M），Oportun Financial Corp同比增速更快（-1.3% vs -1.7%），过去两年INTEGRA LIFESCIENCES HOLDINGS CORP的营收复合增速更高（8.6% vs -0.5%）
英格拉生命科学控股是一家总部位于美国新泽西州普林斯顿的全球医疗器械企业，创立于1989年，主营皮肤再生、神经外科、重建外科与普通外科相关医疗器械。该公司开发的人工真皮是全球首款可规模化量产、用于治疗重度烧伤及其他皮肤创伤的人工皮肤组织。
Oportun Financial Corp是总部位于美国的金融科技公司，专注为信用记录有限或无信用记录的中低收入弱势消费群体提供个人贷款、信用卡、储蓄产品等可负担的金融服务，依托自研AI风控模型保障服务公平性与风险可控。
IART vs OPRT — 直观对比
营收规模更大
IART
是对方的1.8倍
$247.7M
营收增速更快
OPRT
高出0.5%
-1.7%
两年增速更快
IART
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $434.9M | $247.7M |
| 净利润 | — | $3.4M |
| 毛利率 | 50.8% | — |
| 营业利润率 | 5.3% | 2.6% |
| 净利率 | — | 1.4% |
| 营收同比 | -1.7% | -1.3% |
| 净利润同比 | — | -61.0% |
| 每股收益（稀释后） | $-0.03 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IARTOPRT
| Q4 25 | $434.9M | $247.7M | ||
| Q3 25 | $402.1M | $238.7M | ||
| Q2 25 | $415.6M | $234.3M | ||
| Q1 25 | $382.7M | $235.9M | ||
| Q4 24 | $442.6M | $250.9M | ||
| Q3 24 | $380.8M | $250.0M | ||
| Q2 24 | $418.2M | $250.4M | ||
| Q1 24 | $368.9M | $250.5M |
净利润IARTOPRT
| Q4 25 | — | $3.4M | ||
| Q3 25 | $-5.4M | $5.2M | ||
| Q2 25 | $-484.1M | $6.9M | ||
| Q1 25 | $-25.3M | $9.8M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | $-10.7M | $-30.0M | ||
| Q2 24 | $-12.4M | $-31.0M | ||
| Q1 24 | $-3.3M | $-26.4M |
毛利率IARTOPRT
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.5% | — | ||
| Q2 25 | 50.4% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | 54.0% | — | ||
| Q1 24 | 56.1% | — |
营业利润率IARTOPRT
| Q4 25 | 5.3% | 2.6% | ||
| Q3 25 | 2.9% | 6.0% | ||
| Q2 25 | -123.4% | 4.3% | ||
| Q1 25 | -4.0% | 5.6% | ||
| Q4 24 | 8.0% | 89.6% | ||
| Q3 24 | -2.1% | -15.8% | ||
| Q2 24 | -0.7% | -19.6% | ||
| Q1 24 | 1.1% | -12.2% |
净利率IARTOPRT
| Q4 25 | — | 1.4% | ||
| Q3 25 | -1.3% | 2.2% | ||
| Q2 25 | -116.5% | 2.9% | ||
| Q1 25 | -6.6% | 4.1% | ||
| Q4 24 | — | 200.1% | ||
| Q3 24 | -2.8% | -12.0% | ||
| Q2 24 | -3.0% | -12.4% | ||
| Q1 24 | -0.9% | -10.6% |
每股收益（稀释后）IARTOPRT
| Q4 25 | $-0.03 | $0.07 | ||
| Q3 25 | $-0.07 | $0.11 | ||
| Q2 25 | $-6.31 | $0.14 | ||
| Q1 25 | $-0.33 | $0.21 | ||
| Q4 24 | $0.25 | $0.26 | ||
| Q3 24 | $-0.14 | $-0.75 | ||
| Q2 24 | $-0.16 | $-0.78 | ||
| Q1 24 | $-0.04 | $-0.68 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $263.7M | $105.5M |
| 总债务越低越好 | $726.6M | — |
| 股东权益账面价值 | $1.0B | $390.1M |
| 总资产 | $3.6B | $3.3B |
| 负债/权益比越低杠杆越低 | 0.70× | — |
8季度趋势，按日历期对齐
现金及短期投资IARTOPRT
| Q4 25 | $263.7M | $105.5M | ||
| Q3 25 | $267.9M | $104.6M | ||
| Q2 25 | $253.6M | $96.8M | ||
| Q1 25 | $273.3M | $78.5M | ||
| Q4 24 | $273.6M | $60.0M | ||
| Q3 24 | $277.6M | $71.8M | ||
| Q2 24 | $296.9M | $72.9M | ||
| Q1 24 | $663.1M | $69.2M |
总债务IARTOPRT
| Q4 25 | $726.6M | — | ||
| Q3 25 | $736.3M | — | ||
| Q2 25 | $745.9M | — | ||
| Q1 25 | $755.6M | — | ||
| Q4 24 | $760.5M | — | ||
| Q3 24 | $765.3M | — | ||
| Q2 24 | $770.2M | — | ||
| Q1 24 | $775.0M | — |
股东权益IARTOPRT
| Q4 25 | $1.0B | $390.1M | ||
| Q3 25 | $1.0B | $383.9M | ||
| Q2 25 | $1.0B | $376.0M | ||
| Q1 25 | $1.5B | $366.1M | ||
| Q4 24 | $1.5B | $353.8M | ||
| Q3 24 | $1.5B | $327.6M | ||
| Q2 24 | $1.5B | $354.1M | ||
| Q1 24 | $1.6B | $382.0M |
总资产IARTOPRT
| Q4 25 | $3.6B | $3.3B | ||
| Q3 25 | $3.6B | $3.2B | ||
| Q2 25 | $3.7B | $3.2B | ||
| Q1 25 | $4.1B | $3.2B | ||
| Q4 24 | $4.0B | $3.2B | ||
| Q3 24 | $4.1B | $3.3B | ||
| Q2 24 | $4.1B | $3.3B | ||
| Q1 24 | $4.1B | $3.3B |
负债/权益比IARTOPRT
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.8M | $413.4M |
| 自由现金流经营现金流 - 资本支出 | $-5.4M | — |
| 自由现金流率自由现金流/营收 | -1.2% | — |
| 资本支出强度资本支出/营收 | 4.0% | — |
| 现金转化率经营现金流/净利润 | — | 121.45× |
| 过去12个月自由现金流最近4个季度 | $-31.1M | — |
8季度趋势，按日历期对齐
经营现金流IARTOPRT
| Q4 25 | $11.8M | $413.4M | ||
| Q3 25 | $40.9M | $99.0M | ||
| Q2 25 | $8.9M | $104.5M | ||
| Q1 25 | $-11.3M | $101.0M | ||
| Q4 24 | $50.7M | $393.5M | ||
| Q3 24 | $22.5M | $108.5M | ||
| Q2 24 | $40.4M | $107.7M | ||
| Q1 24 | $15.8M | $85.9M |
自由现金流IARTOPRT
| Q4 25 | $-5.4M | — | ||
| Q3 25 | $25.8M | — | ||
| Q2 25 | $-11.2M | — | ||
| Q1 25 | $-40.2M | — | ||
| Q4 24 | $21.1M | — | ||
| Q3 24 | $-7.2M | — | ||
| Q2 24 | $10.7M | — | ||
| Q1 24 | $291.0K | — |
自由现金流率IARTOPRT
| Q4 25 | -1.2% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | -10.5% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | -1.9% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 0.1% | — |
资本支出强度IARTOPRT
| Q4 25 | 4.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 7.1% | — | ||
| Q1 24 | 4.2% | — |
现金转化率IARTOPRT
| Q4 25 | — | 121.45× | ||
| Q3 25 | — | 19.05× | ||
| Q2 25 | — | 15.20× | ||
| Q1 25 | — | 10.34× | ||
| Q4 24 | — | 45.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
OPRT
暂无分部数据
